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Anti-coagulation therapy for stroke
prevention in Atrial Fibrillation (AF) has
been dominated by the drug warfarin for
more than 50 years, yet three recently
approved drugs are viable therapeutic
alternatives to warfarin. However,
according to Dr. Jackson, Program
Director for Applied Health Economics
and Outcomes Research at JSPH, they
are not without challenges to optimize
care for AF patients. He helped provide
a clear and insightful overview of this
topic at a recent Forum. Dr. Jackson
has over 30 years of experience in the
pharmaceutical industry, with much of
this time devoted to clinical research
and the management and practice of
Outcomes Research, including the
transition of clinical evidence into userfriendly cost-effectiveness models.
The framework for Dr. Jackson’s
presentation was based on outcomes
research, which he described as the
“study that studies the studies.” The
purpose of outcomes research, according
to the Agency for Healthcare Research
and Quality (AHRQ), is to examine three
questions: 1) Do patients benefit? 2)
What treatments work best? And, 3) Are
health-care resources well spent?
Jackson first cited the incidence of AF
by explaining that approximately 15% of
all strokes occur in people with AF; the

risk of stroke in patients with untreated
AF averages 5% per year and increases
with advancing age. Jackson emphasized
the chronic and devastating nature of AF
and the importance of understanding the
efficacy and the effectiveness in the real
world of therapeutic options.
For many years, warfarin has been the
only oral anti-coagulant available for
chronic care. Though hugely successful
in terms of stroke prevention, its
use presents numerous challenges in
everyday practice, particularly for
chronically ill, elderly patients. For
example, warfarin is known to have
many interactions with other drugs and
foods, and requires constant monitoring.
There is a narrow therapeutic range,
and the blood test monitoring of the
INR (International Normalized Ratio),
can be a significant barrier for certain
populations as well as caregivers. Most
significant is that warfarin is a leading
cause of adverse drug events and
associated visits to emergency rooms,
Jackson explained.
A new group of anti-coagulants, called
“Novel Oral Anticoagulants” or NOAC,
including dabigatran, rivaroxiban, and
apixaban, open the door for promising
alternatives to warfarin, with fewer
complexities in the treatment regimens.
Dr. Jackson offered an overview of

the major clinical studies, and even
indirectly compared some of the findings,
after warning the audience about the
dangers of indirect comparisons.
Relating this back to outcomes research,
Jackson tackled the questions, “what
treatment works best?” and “are
healthcare resources well spent?”
NOACs, he explained, are unique
compared to warfarin in that they
don’t need INR monitoring, but as
anti-coagulants they still need careful
oversight. In many key outcomes,
NOACs were actually superior or better
than warfarin; however, until real-world
safety and effectiveness are confirmed,
their promise of a superior alternative to
warfarin remains to be seen. He closed
by affirming that most effective therapies
prove cost-effective, and for the NOACs
real-world scenarios will be crucial to
assess their ultimate value.
Throughout his presentation, Dr. Jackson
acknowledged the work and expertise
of Geno J. Merli, MD, Co-Director of
the Vascular Center at Jefferson, and a
national expert on anticoagulant therapy. 
For more information visit:
http://www.theheart.org/columns/
clot-blog.do

